FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 325:1545-1550 November 28, 1991 Number 22 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. The Oka strain of live attenuated varicella vaccine is immunogenic and highly protective, but there has been concern about the risk of zoster after immunization. METHODS. We examined the incidence of zoster, risk factors for it, and measures of immune response in children with leukemia who received the vaccine and in appropriate controls. RESULTS. After a mean follow-up of 4.1 years, zoster was documented in 13 of the 548 vaccinated children with leukemia (2.4 percent). In a subgroup of 96 vaccinated children matched prospectively with 96 children with leukemia who had had natural varicella infections, there were 4 cases of zoster among the vaccinated children and 15 among the controls, for crude incidence rates of 0.80 and 2.46 cases per 100 person-years, respectively (P = 0.01). Of the total of 13 vaccinated children who had zoster, 11 had a skin rash due to varicella-zoster virus, either from the vaccine itself or from breakthrough varicella after household exposure in the period between immunization and the documentation of zoster. In the 268 children who had any type of rash caused by varicella-zoster virus after vaccination, as compared with those who did not have a rash, the relative risk of subsequent zoster was 5.75. For the 21 vaccinated children who received bone marrow transplants, as compared with those who did not, the relative risk of zoster was 7.5. Cell-mediated immunity as assessed by lymphocyte stimulation was lower in 4 children in whom zoster later developed than in 29 controls who had been vaccinated but who did not have zoster (mean stimulation index, 5.1 vs. 23.8; P = 0.0001). CONCLUSIONS. In children with leukemia who receive the live attenuated varicella vaccine, the subsequent incidence of zoster is lower than in children who have natural varicella infections.

Source Information

Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY 10032.

This article has been cited by other articles:

• Whitley, R. J. (2009). A 70-Year-Old Woman With Shingles: Review of Herpes Zoster. JAMA 302: 73-80 [Abstract] [Full Text]  
• Tillieux, S. L., Halsey, W. S., Thomas, E. S., Voycik, J. J., Sathe, G. M., Vassilev, V. (2008). Complete DNA Sequences of Two Oka Strain Varicella-Zoster Virus Genomes. J. Virol. 82: 11023-11044 [Abstract] [Full Text]  
• Marin, M., Meissner, H. C., Seward, J. F. (2008). Varicella Prevention in the United States: A Review of Successes and Challenges. Pediatrics 122: e744-e751 [Abstract] [Full Text]  
• Higashimoto, Y., Ihira, M., Ohta, A., Inoue, S., Usui, C., Asano, Y., Yoshikawa, T. (2008). Discriminating between Varicella-Zoster Virus Vaccine and Wild-Type Strains by Loop-Mediated Isothermal Amplification. J. Clin. Microbiol. 46: 2665-2670 [Abstract] [Full Text]  
• Wood, S. M., Shah, S. S., Steenhoff, A. P., Rutstein, R. M. (2008). Primary Varicella and Herpes Zoster Among HIV-Infected Children From 1989 to 2006. Pediatrics 121: e150-e156 [Abstract] [Full Text]  
• Roderick, M., Ramanan, A. V, Finn, A. (2007). Should the UK introduce varicella vaccine?. Arch. Dis. Child. 92: 1051-1052 [Full Text]  
• Jean-Philippe, P., Freedman, A., Chang, M. W., Steinberg, S. P., Gershon, A. A., LaRussa, P. S., Borkowsky, W. (2007). Severe Varicella Caused by Varicella-Vaccine Strain in a Child With Significant T-Cell Dysfunction. Pediatrics 120: e1345-e1349 [Abstract] [Full Text]  
• Committee on Infectious Diseases, (2007). Prevention of Varicella: Recommendations for Use of Varicella Vaccines in Children, Including a Recommendation for a Routine 2-Dose Varicella Immunization Schedule. Pediatrics 120: 221-231 [Abstract] [Full Text]  
• Quinlivan, M. L., Gershon, A. A., Al Bassam, M. M., Steinberg, S. P., LaRussa, P., Nichols, R. A., Breuer, J. (2007). From the Cover: Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts. Proc. Natl. Acad. Sci. USA 104: 208-212 [Abstract] [Full Text]  
• Zerboni, L., Ku, C.-C., Jones, C. D., Zehnder, J. L., Arvin, A. M. (2005). Varicella-zoster virus infection of human dorsal root ganglia in vivo. Proc. Natl. Acad. Sci. USA 102: 6490-6495 [Abstract] [Full Text]  
• Hambleton, S., Gershon, A. A. (2005). Preventing Varicella-Zoster Disease. Clin. Microbiol. Rev. 18: 70-80 [Abstract] [Full Text]  
• Sato, H., Pesnicak, L., Cohen, J. I. (2003). Varicella-Zoster Virus ORF47 Protein Kinase, Which Is Required for Replication in Human T Cells, and ORF66 Protein Kinase, Which Is Expressed during Latency, Are Dispensable for Establishment of Latency. J. Virol. 77: 11180-11185 [Abstract] [Full Text]  
• Breuer, J. (2003). Live attenuated vaccine for the prevention of varicella-zoster virus infection: does it work, is it safe and do we really need it in the UK?. J Med Microbiol 52: 1-3 [Full Text]  
• Gershon, A. A. (2002). Varicella Vaccine -- Are Two Doses Better Than One?. NEJM 347: 1962-1963 [Full Text]  
• Wills, M R, Carmichael, A J, Sissons, J G P (2002). Vaccines against persistent DNA virus infections. Br Med Bull 62: 125-138 [Abstract] [Full Text]  
• Brisson, M., Edmunds, W. J., Gay, N. J., Miller, E., Seward, J. F., Jumaan, A. O., Galil, K., Wharton, M. (2002). Varicella Vaccine and Shingles. JAMA 287: 2211-2212 [Full Text]  
• Breuer, J (2001). Vaccination to prevent varicella and shingles. J. Clin. Pathol. 54: 743-747 [Abstract] [Full Text]  
• Loparev, V. N., McCaustland, K., Holloway, B. P., Krause, P. R., Takayama, M., Schmid, D. S. (2000). Rapid Genotyping of Varicella-Zoster Virus Vaccine and Wild-Type Strains with Fluorophore-Labeled Hybridization Probes. J. Clin. Microbiol. 38: 4315-4319 [Abstract] [Full Text]  
• Loparev, V. N., Argaw, T., Krause, P. R., Takayama, M., Schmid, D. S. (2000). Improved Identification and Differentiation of Varicella-Zoster Virus (VZV) Wild-Type Strains and an Attenuated Varicella Vaccine Strain Using a VZV Open Reading Frame 62-Based PCR. J. Clin. Microbiol. 38: 3156-3160 [Abstract] [Full Text]  
• Brunell, P. A., Argaw, T. (2000). Chickenpox Attributable to a Vaccine Virus Contracted From a Vaccinee With Zoster. Pediatrics 106: 28e-28 [Abstract] [Full Text]  
• GERSHON, A. (1998). Varicella: to vaccinate or not to vaccinate?. Arch. Dis. Child. 79: 470-471 [Full Text]  
• Lim, Y J, Chew, F T, Tan, A Y S, Lee, B W (1998). Risk factors for breakthrough varicella in healthy children. Arch. Dis. Child. 79: 478-480 [Abstract] [Full Text]  
• Spingarn, R. W., Benjamin, J. A., Meissner, H. C. (1998). Universal Vaccination against Varicella. NEJM 338: 683-684 [Full Text]  
• MacFarlane, L. L., Sanders, M. L., Carek, P. J. (1997). Concerns Regarding Universal Varicella Immunization: Time Will Tell. Arch Fam Med 6: 537-541 [Abstract]  
• Broyer, M., Tete, M. J., Guest, G., Gagnadoux, M. F., Rouzioux, C. (1997). Varicella and Zoster in Children After Kidney Transplantation: Long-term Results of Vaccination. Pediatrics 99: 35-39 [Abstract] [Full Text]  
• Kost, R. G., Straus, S. E. (1996). Postherpetic Neuralgia -- Pathogenesis, Treatment, and Prevention. NEJM 335: 32-42 [Full Text]  
• Plotkin, S. (1994). Vaccines for varicella-zoster virus and cytomegalovirus: recent progress. Science 265: 1383-1385  
• Stoeckle, M. Y., Douglas, R. G. Jr (1994). Infectious Diseases. JAMA 271: 1677-1679 [Abstract]  
• Lieu, T. A., Cochi, S. L., Black, S. B., Halloran, M. E., Shinefield, H. R., Holmes, S. J., Wharton, M., Washington, A. E. (1994). Cost-effectiveness of a Routine Varicella Vaccination Program for US Children. JAMA 271: 375-381 [Abstract]